scholarly article | Q13442814 |
P50 | author | Shigeru Morikawa | Q88820659 |
Shuetsu Fukushi | Q89375432 | ||
Alexander N. Freiberg | Q93156043 | ||
Sabarish V Indran | Q117536105 | ||
Nandadeva Lokugamage | Q117812116 | ||
Birte Kalveram | Q121296437 | ||
Olga Lihoradova | Q121296444 | ||
Terry L Juelich | Q121296446 | ||
Tetsuro Ikegami | Q40311693 | ||
P2093 | author name string | Bin Gong | |
Chien-Te K Tseng | |||
Terence E Hill | |||
P2860 | cites work | Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action | Q24672548 |
Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse | Q27305612 | ||
Complete Genome Analysis of 33 Ecologically and Biologically Diverse Rift Valley Fever Virus Strains Reveals Widespread Virus Movement and Low Genetic Diversity due to Recent Common Ancestry | Q27478367 | ||
Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya | Q27482900 | ||
RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses | Q27487321 | ||
Rapid Accumulation of Virulent Rift Valley Fever Virus in Mice from an Attenuated Virus Carrying a Single Nucleotide Substitution in the M RNA | Q27491320 | ||
Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep | Q40358602 | ||
Rift Valley fever virus: an unrecognized emerging threat? | Q40360325 | ||
Potential for North American mosquitoes to transmit Rift Valley fever virus | Q40398345 | ||
Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. | Q40453546 | ||
Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus | Q40556157 | ||
Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys | Q40557158 | ||
Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. | Q40579610 | ||
Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts | Q40589545 | ||
Improved Recovery of Rabies Virus from Cloned cDNA Using a Vaccinia Virus‐Free Reverse Genetics System | Q40629273 | ||
Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. | Q40632227 | ||
Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation | Q40642621 | ||
Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids | Q40645618 | ||
Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle | Q40645625 | ||
Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. | Q40679919 | ||
Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep | Q40753243 | ||
Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine | Q40759549 | ||
Vector Competence of Senegalese Aedes fowleri (Diptera: Culicidae) for Rift Valley Fever Virus1 | Q40784948 | ||
Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes | Q40795447 | ||
Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development | Q40814834 | ||
The development of a formalin-killed Rift Valley fever virus vaccine for use in man. | Q40987065 | ||
Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase | Q41602853 | ||
Langerhans cells: not your average dendritic cell | Q42281644 | ||
The Homingbac baculovirus cloning system: An alternative way to introduce foreign DNA into baculovirus genomes | Q43168948 | ||
Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. | Q43559384 | ||
Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung | Q47362441 | ||
Double-hexahistidine tag with high-affinity binding for protein immobilization, purification, and detection on ni-nitrilotriacetic acid surfaces. | Q50732326 | ||
Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. | Q52533947 | ||
Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II | Q59098636 | ||
Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR | Q78666553 | ||
TFIIH plays an essential role in RNA polymerase I transcription | Q27934158 | ||
Structure and function of the spleen | Q28264813 | ||
A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A | Q28268795 | ||
Cloning and characterization of murine p16INK4a and p15INK4b genes | Q28512180 | ||
Molecular structure of human TFIIH | Q28611504 | ||
Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase | Q29620280 | ||
TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. | Q33198557 | ||
A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. | Q33316823 | ||
Double-stranded RNA-activated protein kinase PKR of fishes and amphibians: varying the number of double-stranded RNA binding domains and lineage-specific duplications | Q33321981 | ||
Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation | Q33406230 | ||
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity | Q33787696 | ||
Translational control of viral gene expression in eukaryotes | Q33935121 | ||
Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention | Q33960690 | ||
Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice | Q34031858 | ||
Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice. | Q34097995 | ||
Hemorrhagic fever viruses as biological weapons: medical and public health management | Q34126496 | ||
The pathogenesis of Rift Valley fever | Q34191969 | ||
Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep | Q34221766 | ||
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells | Q34887778 | ||
Rift Valley fever virus | Q34971963 | ||
Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals | Q36484009 | ||
Lymph node mapping in the mouse | Q36590616 | ||
Rift valley fever vaccines | Q37393780 | ||
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase | Q39195523 | ||
NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. | Q39547955 | ||
The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice | Q39588385 | ||
Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs | Q39601913 | ||
Transfection of insect cell lines using polyethylenimine | Q39918460 | ||
NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription | Q39960501 | ||
Antigen-capture ELISA for the detection of Rift Valley fever virus nucleoprotein using new monoclonal antibodies | Q40299380 | ||
Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene | Q40311587 | ||
Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine | Q40317212 | ||
DC-SIGN as a receptor for phleboviruses | Q40318139 | ||
Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus | Q40321756 | ||
Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance | Q40327417 | ||
The pathogenesis of Rift Valley fever virus in the mouse model | Q40348320 | ||
P433 | issue | 14 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Rift Valley fever | Q326638 |
Rift Valley fever virus | Q14276794 | ||
Rift Valley fever phlebovirus | Q24809101 | ||
P1104 | number of pages | 12 | |
P304 | page(s) | 7650-7661 | |
P577 | publication date | 2012-05-09 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine | |
P478 | volume | 86 |
Q59335452 | A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice |
Q43167996 | Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain |
Q37509225 | Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR. |
Q56881173 | Bunyaviruses: from transmission by arthropods to virus entry into the mammalian host first-target cells |
Q28486276 | Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus |
Q33705717 | Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs |
Q35126733 | Development of a novel, single-cycle replicable rift valley Fever vaccine |
Q44170263 | Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells |
Q35792819 | MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters |
Q36489477 | Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever. |
Q27027003 | Novel approaches to develop Rift Valley fever vaccines |
Q36816140 | Novel vaccine strategies against emerging viruses |
Q36879979 | Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge |
Q39251803 | Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. |
Q37006803 | Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice |
Q36501737 | Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. |
Q36326847 | Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates |
Q37509231 | The two faces of Rift Valley fever virus virulence factor NSs: The development of a vaccine and the elucidation of pathogenesis |
Search more.